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Abstract: A spider-transmitted fungus (Rhizopus microspo-
rus) that was isolated from necrotic human tissue was found to
harbor endofungal bacteria (Burkholderia sp.). Metabolic
profiling of the symbionts revealed a complex of cytotoxic
agents (necroximes). Their structures were characterized as
oxime-substituted benzolactone enamides with a peptidic side
chain. The potently cytotoxic necroximes are also formed in
symbiosis with the fungal host and could have contributed to
the necrosis. Genome sequencing and computational analyses
revealed a novel modular PKS/NRPS assembly line equipped
with several non-canonical domains. Based on gene-deletion
mutants, we propose a biosynthetic model for bacterial
benzolactones. We identified specific traits that serve as genetic
handles to find related salicylate macrolide pathways (lobata-
mide, oximidine, apicularen) in various other bacterial genera.
Knowledge of the biosynthetic pathway enables biosynthetic
engineering and genome-mining approaches.
A brief encounter between a spider and an Australian
woman in her garden in the late 1980s caused immense
suffering to the latter. It started with a single prick in her little
finger, which led to a mixed infection followed by necrosis
that could only be stopped by multiple doses of amphotericin
and below-elbow amputation of the right hand. Cultures of
samples taken from deep necrotic tissue grew a fungus that
was later identified as the zygomycete fungus Rhizopus
microsporus Tieghem var. microsporus CBS 308.87.[1] Fungal
strains of this species are well known as plant pathogens that
cause, among others, rice seedling blight.[2] Beyond plant
diseases, there have been severe incidents of human infec-
tions, in particular in immunocompromised patients, some of
which led to necroses in infected areas.[3] Insects and spiders
have repeatedly been reported as vectors that implant
zygomycete spores into subcutaneous tissue.[3]
We have discovered that certain R. microsporus strains
harbor bacteria that live within the fungal hyphae.[4] These
bacterial endosymbionts have been found to be responsible
for the production of the antimitotic rhizoxin complex, the
causative agent of rice seedling blight, which had initially
been attributed to the fungi.[5] Furthermore, the endofungal
bacteria control their hosts vegetative reproduction through
spores, which facilitates the symbiosis and its dissemination
across the globe.[6] It is intriguing that the fungal strain that
was transmitted by the spider bite contains endofungal
bacteria too.[7] These bacterial endosymbionts (Burkholderia
sp. HKI-0404, isolate B8; Figure 1A), however, comprise
a phylogenetically distinct clade of the Rhizopus symbionts
and are only remotely related to the other seven studied
isolates from other continents.[7] Apart from their ability to
produce the antimitotic rhizoxin complex,[8] the full metabolic
potential of the B8 endosymbionts has remained elusive.
Herein, we report the discovery and full characterization of
novel cytotoxic benzolactones and elucidate their biosynthet-
ic pathways from the spider-transmitted Rhizopus endo-
symbionts. Using genomics, we identify a biosynthetic signa-
ture of related biosynthetic gene clusters in diverse bacterial
phyla, with implications for understanding the origins of
benzolactones from diverse sources.
Figure 1. Bacterial endosymbionts of spider-transmitted fungus and
their metabolic profiles. A) Burkholderia sp. strain B8 and Rhizopus
microsporus monitored by fluorescence microscopy: staining with
Calcofluor White and Syto9 Green. B) HPLC profiles of Burkholderia sp.
in pure culture (B8) and in symbiosis with the host (F8): extracted ion
chromatograms [M+H]+ or PDA (200–600 nm).
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To uncover natural products that could have contributed
to the necrosis caused by the spider-transmitted fungal
infection, we compared the metabolic profiles of eight
different isolates of bacterial symbionts. We found that the
Australian isolate Burkholderia sp. B8 produces the antimi-
totic rhizoxin complex at lower titers than strains B1–B7,
which are associated with hosts from geographically distant
areas. Furthermore, HPLC analyses revealed a family of
compounds that are unique to strain B8 (Figure 1B). MS
network analysis indicated the presence of several congeners,
and their similar MS/MS fragmentation patterns pointed to
the presence of stereoisomeric pairs of congeners. A series of
optimizations, the use of absorber resin, adjusting preparative
HPLC conditions, and highly reduced acidic conditions
during the workup, eventually enabled the isolation of the
main components (1–4) from the extract of an upscaled
symbiont culture (7 L).
The pure compounds were subjected to a panel of
cytotoxicity assays probing the antiproliferative effects
against mammalian cell lines (HUVEC, K-562, THP-1,
HEK-293) and cytotoxicity against HeLa cells. We found
that 1 is the most potent against HUVEC cells (GI50 0.60 mm),
whereas 4 most effectively inhibits the growth of THP-1 cells
(GI50 0.44 mm). All compounds are highly cytotoxic against
HeLa cells (CC50 1: 1.93 mm, 3 : 0.87 mm, and 4 : 1.09 mm). In
addition, 1 selectively inhibits the yeast-like fungus Sporobo-
lomyces salmonicolor, whereas other tested fungal and
bacterial strains are not affected. The marked cytotoxicity
of the compounds suggests that they may have contributed to
the formation of necrotic tissue following spider-transmitted
Rhizopus infection. To scrutinize this scenario, we analyzed
the metabolic profile of the holobiont and found that these
bacteria-derived cytotoxins are also produced in symbiosis
with the fungal host (Figure 1B).
The structures of compounds 1–4 were fully elucidated by
1D and 2D NMR experiments and chemical derivatization
(Figure 2A). According to chemical shifts and 2D NMR
correlations, 1 and 2 have a benzolactone core structure with
an oxime side chain that corresponds to the planar structure
of CJ-12,950 (5 ; Figure 2B), a natural product isolated from
the zygote fungus Mortierella verticillata NRRL6337.[9] How-
ever, NMR and MS data indicated that 1 and 2 have
additional side chains attached to C-13, according to long-
range couplings from H-13 to C-24 across the ester bonds. In
compound 1, the side chain consists of a lysine residue
connected to a 3-hydroxybutyric acid moiety. HRMS data,
MS fragmentation, and NMR correlations revealed that 2 is
a deoxy derivative of 1 in which the 3-hydroxybutyryl is
replaced by a butyryl residue (Figure 2A). The smaller
congeners, compounds 3 and 4, have planar structures that
match those reported for the 20Z- and 20E-isomers CJ-12,950
(5) and CJ-13,357 (6) from M. verticillata.[9]
Since only the two-dimensional structures of 5 and 6 had
been reported,[9] we set out to elucidate the configurations of
all stereocenters of the symbiont metabolites. We identified
the absolute configurations of the OH groups at C-10 (S) and
C-13 (R) by Mosher ester analysis. NOE couplings indicated
that the lactone hydroxy group at C-15 is S-configured and
corroborated the architecture of the cis-epoxide (J11-12=
4.0 Hz), with additional NOE signals of H-12 and H-11
confirming a similar orientation to H-10, H-13, and H-15 on
the macrocyclic ring. Using Marfeys reagent, we determined
the configuration of lysine (l) in the side chain of 1, and
Mosher ester analysis in combination with LC revealed
R configuration for the hydroxybutyrate moiety (Figure 2A).
Due to their origin and prominent structural motif, we named
the new compounds necroximes A–D (1–4).
The necroximes are new additions to the family of
bacterial salicylate macrolides, also referred to as benzolac-
tone enamides, which act as selective inhibitors of mammalian
vacuolar-type (H+)-ATPases (V-ATPases) and thus effec-
tively inhibit tumor cell growth.[10] The origins of benzolac-
Figure 2. Structures of symbiont-derived benzolactones and related
natural products. A) Structure elucidation of necroximes A–D (1–4),
selected 2D NMR data, and experiments to confirm absolute config-
urations. B) Benzolactone structures from diverse producer strains.
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tone enamides are surprisingly diverse: in addition to the
fungi-derived compounds 5 and 6, important examples of
these natural products are lobatamide (7) from a tunicate,[11]
salicylihalamide (8) from a sponge,[12] apicularen (9) and
cruentaren A (10) from myxobacteria,[13] and oximidines (11)
from pseudomonads[14] (Figure 2B). Considering the clinical
importance of benzolactone enamides and the range of
known structures, it is remarkable that to date the biosyn-
thesis of the entire class of bacterial benzolactones has
remained elusive.
To gain insight into the molecular basis of necroxime
biosynthesis, we sequenced the genome of Burkholderia sp.
B8 using the Illumina NextSeq platform. In the genome of
strain B8, we identified a 66 kb gene locus (see the Supporting
Information; Gene accession number MN734804) that
appeared to be the best candidate for the necroxime (nec)
biosynthetic gene cluster (Figure 3A). The nec gene locus
comprises genes (necA–J) for a multimodular trans-AT PKS/
NRPS hybrid assembly line that is largely colinear with the
backbone of the necroximes. An encoded cytochrome P450
monooxygenase (NecI) is likely involved in the final oxygen-
ations. Furthermore, a phylogenetic analysis of the ketosyn-
thase (KS) domains of the encoded PKS modules[15] revealed
KS substrate specificities that match with predicted biosyn-
thetic intermediates. Likewise, computational analyses of the
NRPS adenylation domain specificities[16] corroborated the
correct building blocks. The absolute configurations of the
ketoreductase (KR)-generated hydroxy groups were con-
firmed by bioinformatics (Supplementary Information).
To unequivocally assign the nec gene cluster to necroxime
production, we created targeted gene-deletion mutants of
strain B8 (DnecA and DnecF) by using knockout plasmids
based on the enhanced double-selection plasmid pGL42a[17]
(Figure 3A), and verified them by PCR. Since the metabolic
Figure 3. Molecular basis of necroxime biosynthesis. A) Organization of the nec biosynthetic gene cluster, strategy for gene deletion, and
metabolic profiles of mutants. KanR=kanamycin resistance cassette. Dark blue: NRPS genes, light blue: PKS genes, orange: a regulatory gene,
red: a cytochrome P450 monooxygenase gene, gray/light brown: hypothetical/additional genes. B) Model for necroxime biosynthesis on a PKS/
NRPS assembly line. KS=ketosynthase (cyan for canonical; gray for non-elongating); KR=ketoreductase; DH=dehydratase (light blue for
canonical; dark red for double-bond shift; violet and orange for non-canonical); Oxy=oxygenase; MT=methyltransferase; TE= thioesterase;
CYP= cytochrome P450 monooxygenase; ACP (yellow sphere)=acyl carrier protein; C=condensation; A=adenylation; PCP (blue sphere)=pep-
tidyl carrier protein; AT=acyl transferase; gray spheres=possibly inactive domains.
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profile of DnecF was devoid of necroximes,
the identity of the first gene cluster respon-
sible for the production of a benzolactone
enamide was proven. Moreover, while
DnecA was unable to produce necroxi-
mes A (1) and B (2), necroximes C (3) and
D (4) were still observed in extracts of this
mutant (Figure 3A), thus indicating that
NecA is responsible for the formation and
attachment of the peptide side chain in
1 and 2.
The deduced assembly line features
a number of unusual PKS domains and
module architectures that account for the
structural signatures of the necroximes
(Figure 3B). The first three modules are
obviously in charge of installing the rare
oxime side chain by means of specialized
oxygenase (OXY), dehydratase (DH), and
methyltransferase (MT) domains that
modify the side chain of the glycine
primer. In addition to the tentative
oxime-forming DH, the PKS harbors
a number of non-canonical DH domains
and module architectures, such as two DH
domains in one module (M8–11). To learn
more about the functions of these DH
domains, we performed a multiple
sequence alignment and inferred a phylog-
eny (Figure 4A and the Supporting Infor-
mation). The DH domains cluster into four
different groups in which some of the
sequences deviate from the typical cata-
lytic dyad.[18] DH domains from modules 9
and 11 fall into a clade with so-called
double-bond shift domains[19] and may thus
be involved in two double-bond shifts
during necroxime biosynthesis. The most
unusual DH domain, however, is located in
the terminal PKS module, which is impli-
cated in the formation of the salicylate
moiety (Figure 3B).
To date, salicylate macrolactone bio-
synthesis has been exclusively studied in
fungi. In the zearalenone, hypocemycin,
and radicicol biosynthetic pathways,[20] the
salicylate ring is formed through the action
of a so-called product template (PT)
domain.[21] No equivalents to these PT
domains have been reported for bacterial
modular PKSs. Notably, DH and PT
domains evolved from a common ancestor
since the two families have conserved
catalytic dyads and tertiary structures.[21b]
Therefore, the DH in the terminal module
(M13) could, in principle, meet the require-
ments to catalyze salicylate formation in
a manner analogous to the fungal path-
ways.
Figure 4. Genome mining for benzolactone assembly lines. A) Phylogenetic analysis of DH
domains and their conserved motifs (Weblogo) and comparison of canonical (HXXXGXXXXP
and DXXXQ) and non-canonical bacterial DH domains. DB=double bond. Asterisks indicate
DB-shift domains from other assembly lines. DH domains from nec PKS are shown in bold.
DH2 (orange) was omitted from the analyses. B) Organizations of tentative benzolactone
biosynthesis gene clusters identified by genome mining using PT-like DH sequence.
C) Genomics-guided identification of oximidine III in P. baetica. D) Deduced PKS/NRPS
assembly lines and predicted metabolite backbones that correspond to known benzolac-
tones. Color code as in Figure 3.
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Since the motifs of this DH domain are markedly different
from the canonical ones (Figure 4A), we employed the amino
acid sequence of the terminal DH as a bioinformatic handle to
screen bacterial genomes for related biosynthetic machineries
(Figure 4B). By means of this genome-mining approach, we
identified ten related PKS/NRPS gene clusters that tenta-
tively code for salicylate macrolactones. In the genomes of
one Chromobacterium sp. and four Pseudomonas spp., we
identified gene clusters that could code for the biosynthesis of
oximidines (11).[14] In contrast to the necroximes, the oximi-
dines lack an N-acylated lysine side chain, which is reflected
by the missing NRPS1 gene. As a proof of concept, we
investigated culture extracts of the fish pathogen Pseudomo-
nas baetica and found that these bacteria indeed produce
oximidine III (Figure 4C). Furthermore, we detected an
orthologous gene cluster in the genome of the apicularen
producer Chondromyces apiculatus (Figure 4D). Notably,
apicularen A (9) is a benzolactone that lacks the oxime
moiety. In agreement with the prediction, the deduced
assembly line lacks the designated domains for oxime
formation and is colinear with the apicularen backbone.
Next, four related gene clusters were identified in the
genomes of two Allorhizobium spp., a Rhizobium sp., and
the rhizosphere bacterium Gynuella sunshinyii, which has
been identified as a promising source of natural products.[22]
The deduced PKS/NRPS assembly lines, which harbor addi-
tional oxygenase domains that may insert oxygens into the
polyketide backbone, code for the biosynthesis of lobatamide
or derivatives thereof (7; Figure 4D).[23] Based on the high
conservation of the biosynthetic machineries exclusively
among bacteria, we suggest that endosymbionts are the true
producers of lobatamide in the tunicate Aplidium lobatum.[11]
Likewise, we propose that salicylihalamide (8) from the
demosponge Haliclona sp.[12a] and the CJ compounds (5 and
6) from the fungus M. verticillata[9] are of bacterial origin.
In conclusion, from the endobacteria of a spider-trans-
mitted fungus, we isolated and characterized a complex of
cytotoxic agents, two of which represent the largest known
bacterial benzolactone oximes, a class of natural products
with high potential for antitumor therapies. Despite their
pharmacological relevance, the biosynthetic machineries
responsible for macrolactone production have remained
enigmatic. Herein, we unravel the molecular basis for
bacterial benzolactone formation and provide the first
model for their biosynthesis, which involves unusual oxime
formation and aromatization steps. The knowledge of the
biosynthetic pathway sets the stage for future bioengineering
and genome-mining approaches. As a proof of concept, we
showed that an unprecedented PT-like DH domain can be
used to discover cryptic gene clusters in diverse bacterial
genera that might code for various known V-ATPase inhib-
itors. This finding challenges the biogenetic origin of several
natural products previously isolate from sponges, tunicates,
and fungi, and suggests that they may actually be biosynthe-
sized by bacterial endosymbionts. Thus, beyond setting an
unusual example of hypothesis-based drug discovery in the
context of human disease, our work has implications for
biosynthetic engineering, genome mining, and ecology.
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